Pascal Wolter
Clinique Saint-Joseph · 164 works · 8,497 citations · h-index 36
Top works
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
- Toward Minimal Residual Disease-Directed Therapy in Melanoma
- Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib
- The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
- Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
- Sunitinib-related thyroid dysfunction: A single-center retrospective and prospective evaluation
- Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases
- Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review
- A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
- 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)
- Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study
- Patient adherence to oral anticancer drugs: an emerging issue in modern oncology.
- Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
- Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors
- Prognostic impact of baseline serum C ‐reactive protein in patients with metastatic renal cell carcinoma ( RCC ) treated with sunitinib
- Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
- Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma